Skip to main content
CMRAOTCdelisted

Comera Life Sciences Holdings, Inc.

Biopharma developer (SEC filing verified)·Woburn, MA, United States·CEO: Mr. Michael G. Campbell CPA
ImmunologyDermatology

CMRA evidence brief

What we can confirm

No verified snapshot fields are available yet.

What it means

The company data is ready for cross-source review; unsupported conclusions remain unknown.

What to watch

Watch the next source-backed data update.
BioSniper AIPage evidence connected

Prepared research question

What matters most for CMRA—catalysts, financial risk and supporting evidence?

Run cited research

Traceable citations · Unknowns marked

1.6/10

BioSniper Score

Based on 3 of 6 signals

Limited data coverage

Market Cap

$3K

Cash Runway

3.2 mo

Lead Asset

CLS-001

Next Catalyst

Financial data as of Sep 30, 2023.

Tracking 1 pipeline candidate for Comera Life Sciences Holdings, Inc..

Run Comera Life Sciences Holdings, Inc. through your own thesis

Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.

Your protocol can:

  • Turn available Comera Life Sciences Holdings, Inc. facts into screen rules or deeper checks
  • Show cited findings, blockers, and unresolved evidence together
  • Save the logic and rerun it as the company evidence changes
Run a thesis on this company — freeRun a thesis on this company

Score breakdownBased on 3 of 6 signals · derived from public data

Cash Runway0.9

3.2 months

Financial Health0.5

OCF -$2M

Pipeline MaturityN/A

No tracked pipeline phase

Pipeline Breadth3.3

1 candidate

Catalyst MomentumN/A

No upcoming catalysts tracked

Insider SignalN/A

No insider transactions in the last 180 days

Runway

Pipeline

Financials

Institutional Holdings

Source: SEC Form 13F · as of Sep 2023

Institutional holders

15

Total value held

$207K

Showing top 10 of 15 institutional holders of Comera Life Sciences Holdings, Inc.. Open the full 13F history after sign-in.

Short Interest

as of May 20, 2026
% of float
1.4%
Days to cover
0.8
Shares short
281,553
Daily short volume
-

Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →

CMRA short interest

Governance

Frequently asked questions

Who is the CEO of Comera Life Sciences Holdings, Inc.?

Mr. Michael G. Campbell CPA is the chief executive officer of Comera Life Sciences Holdings, Inc. (CMRA).

Where is Comera Life Sciences Holdings, Inc. headquartered?

Comera Life Sciences Holdings, Inc. (CMRA) is headquartered in Woburn, MA, United States.

What therapeutic areas does Comera Life Sciences Holdings, Inc. focus on?

Comera Life Sciences Holdings, Inc. develops therapies across Immunology, Dermatology.

925 companies232,681 SEC filings21,419 clinical trials100% citation-verification pass rate (7d)How we verify →

The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.